Chengcheng Hu, Ph.D. is an Assistant Professor of Biostatistics in the Department of Biostatistics at the University of Arizona Public Health Epi/Biostats Division. Dr. Hu has extensive research experience in both statistical methodology and collaborative clinical studies.
Dr. Hu's research in statistical methodology has been motivated by problems encountered in the analysis of medical data. His current interest, arising from studies of viral and human genetics in HIV-infected patients, is to develop innovative methods to investigate the relationship between high-dimensional genetic information and longitudinal markers or survival endpoints. Other areas he has worked on include the modeling of measurement error and missing data and the strategy of design and analysis of clinical trials.
Since 2001 Dr. Hu has served as a Senior Statistician in the Statistical and Data Management Center of the Pediatric AIDS Clinical Trials Group (PACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT), both of which are NIH funded multicenter, multidisciplinary clinical trials groups for HIV-infected children, adolescents, and pregnant women. In this position Dr. Hu has provided statistical expertise and leadership in the development, conduct and analysis of HIV therapeutic clinical trials of various phases and types, including Phase I/II, Phase III, pharmacokinetic, and smaller pilot studies.
Publications:
Healy, B.C., De Gruttola, V.G., and Hu, C. (2008). Accommodating uncertainty in tree set for function estimation. Statistical Applications in Genetics and
Molecular Biology, 7, Iss. 1, Article 5.
Available at: http://www.bepress.com/sagmb/vol7/iss1/art5
Capparelli, E.V., Aweeka, F., Hitti, J., Stek, A., Hu, C., Burchett, S.K., Best, B., Smith, E., Read, J.S., Watts, H., Nachman, S., Thorpe, E.M., Spector, S.A., Jimenez, E., Shearer, W.T., Foca, M., Mirochnick, M., for the PACTG
1026S and P1022 Study Teams (2008). Chronic administration of nevirapine during pregnancy: impact of pregnancy on pharmacokinetics. HIV Medicine
9(4), 214-220.
Read, J.S., Best, B.M., Stek, A.M., Hu, C., Capparelli, E.V., Holland, D.T., Burchett, S.K., Smith, M.E., Sheeran, B.C., Shearer, W.T., Febo, I., and Mirochnick, M. (2008). Pharmacokinetics of new 625 mg nelfinavir formula-
tion during pregnancy and postpartum. HIV Medicine, 9(10), 875-882.
Mirochnick, M., Best, B.M., Stek, A.M., Capparelli, E., Hu, C., Burchett, S.K., Holland, D.T., Smith, E., Gaddipati, S., Read, J.S., for the PACTG 1026S Study Team (2008). Lopinavir exposure with an increased dose during pregnancy. Journal of Acquired Immune Deficiency Syndromes, 49(5), 485-491.
Weinberg, A., Dickover, R., Britto, P., Hu, C., Patterson-Bartlett, J., Kraymer, J., Gutzman, H., Shearer, W., Gelman, R., Rathore, M., McKinney, R., and the
PACTG 1021 Team (2008). Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy. AIDS, 22(17),
2267-2277.
Garvie, P.A., Cremeens, J., Gaur, A.H., Flynn, P.M., Belzer, M., McSherry, G., and Hu, C. for the Pediatric AIDS Clinical Trials Group 1036A Study Team (2009). Development of a directly observed therapy adherence intervention Chengcheng Hu 5 for adolescents with Human Immunodeficiency Virus-1: application of focus
group methodology to inform design, feasibility and acceptability. Journal of
Adolescent Health, 44(2), 124-132.